

Examiner: A. R. Hughes

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98 and the Examiner is respectfully requested to consider the listed references.


It was noted that the Form PTO-1449 and accompanying copies of documents that were filed on September 10, 2004 are not listed on the USPTO’s Patent Application Information Retrieval (PAIR) system. Therefore, the Form PTO/SB/08 that is filed concurrently herewith lists these documents, and copies of the documents (that are not U.S. patents or U.S. patent applications) are also filed concurrently herewith. A Third Information Disclosure Statement, filed August 12, 2005, corrected typographical errors for certain documents listed on the September 10, 2004 Form PTO-1449, and copies of those documents were also filed August 12, 2005. This submission includes copies of all of the documents listed on the accompanying PTO/SB/08, including any which duplicate those of the August 12, 2005 submission, for the Examiner’s convenience.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits. The Office Action mailed December 19, 2006 was a nonfinal written requirement to restrict, setting a one month period for response, and thus not an Office Action on the merits (*see*, M.P.E.P. §810).

It is believed that no fees are required for this IDS submission. However, should the U.S. Patent and Trademark Office determine any fee is required and/or that any refund is owed for this application, then the Commissioner is hereby authorized and requested to charge the required fee(s) and/or credit the refund(s) due to Deposit Account No. 04-0100 of the Applicants' undersigned attorneys/agents.

Dated: March 19, 2007

Respectfully submitted,

By 
Jonathan M. Spehner, Ph.D.
Registration No.: 57,268
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete If Known		
			Application Number	10/762,566-Conf. #3220	
			Filing Date	January 23, 2004	
			First Named Inventor	Richard Franklin	
			Art Unit	1614	
Examiner Name	A. R. Hughes				
Sheet	1	of	1	Attorney Docket Number	20342/1202529-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	USPD13	US-5,306,709	4-26-1994	Gewirtz	
	USPD14	US-6,037,346	3-14-2000	Doherty, Jr. et al.	
	USPD15	US-6,156,753	12-5-2000	Doherty, Jr. et al.	
	USPD16	US-6,299,900	10-9-2001	Reed et al.	
	USPD17	US-6,331,543	12-18-2001	Garvey et al.	
	USPD18	US-6,376,242	4-23-2002	Hanson	
	USPD19	US-6,403,597	6-11-2002	Wilson et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	FPD14	EP 0 514 917 B1	11-25-1992	Egis Gyogyszergyar Budapest X (HU)		
	FPD15	WO 93/09794	5-27-1992	University of Pennsylvania		
	FPD16	WO 99/38496	8-5-1999	R.P. Scherer Corporation		
	FPD17	WO 02/062322 A2	8-15-2002	Jallal Messadek		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	NPLD17	International Search Report in connection with International Application No. PCT/CA2004/000096.		
	NPLD18	PESCATORE, Scott L., et al., "Anagrelide: a novel agent for the treatment of myeloproliferative disorders", Exp. Opin. Pharmacother., 2000, 1: 537-546.		
	NPLD19	GRIESSHAMMER, Martin, et al., "Current treatment practice for essential thrombocythaemia in adults", Exp. Opin. Pharmacother., 2001, 2: 385-393.		
	NPLD20	LANE, William J., et al., "Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation", Experimental Hematology, 2001, 29: 1417-1424.		
	NPLD21	ERUSALIMSKY, Jorge D., et al., "Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline (RL603)?", Experimental Hematology, 2002, 30: 625-627.		
	NPLD22	STOREN, Elizabeth C., et al., "Long-term use of anagrelide in young patients with essential thrombocythemia", Blood, February 15, 2001, Vol. 97, No. 4, 863-866.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

{W:\203421\202529us1\00994595.DOC [REDACTED]}